Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …

Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy
characterised by limited treatment options and a poor prognosis. At relapse after platinum …

Background Malignant pleural mesothelioma is a highly aggressive cancer with poor
prognosis and few treatment options following progression on platinum-containing …

Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …

Background MPM is an aggressive malignancy of increasing prevalence and poor
prognosis. At relapse after platinum-based (pb) CT, single agent CT is commonly used and …

Background The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an
antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical …

Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to
asbestos. Patients with malignant pleural mesothelioma have poor outcomes with …

Background Malignant pleural mesothelioma (MPM) has few treatment options.
Pembrolizumab showed preliminary clinical benefit in programmed death ligand 1 (PD-L1) …

Background: The programmed death receptor 1 (PD-1) pathway is implicated in evasion of
the antitumor immune response. Pembrolizumab is a potent, highly selective humanized …

Pleural mesothelioma is an aggressive and incurable cancer1 with a rising global incidence,
2 especially in low-income countries. Pleural mesothelioma is always fatal, despite attempts …